Therapeutic Asset Ratings

480 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Irinotecan Solid Tumor	Mirati Therapeutics Inc.	P4	BB (66)
(+)-VINCRISTINE Solid Tumor	Pfizer	P4	B (63)
Atezolizumab Solid Tumor	Hoffmann-La Roche	P2/3	B (62)
Durvalumab Solid Tumor	GlaxoSmithKline	P4	B (61)
Rivoceranib Solid Tumor	Beidahuang Industry Group General Hospital	P3	B (61)
Cyclophosphamide Solid Tumor	National Cancer Institute (NCI)	P3	B (60)
Famitinib Solid Tumor	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	P3	B (60)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER Solid Tumor	Jiangsu HengRui Medicine Co., Ltd.	P3	B (60)
LENVATINIB Solid Tumor	Tongji Hospital	P3	B (60)
Osimertinib Solid Tumor	Innovent Biologics (Suzhou) Co. Ltd.	P3	B (60)
ETOPOSIDE Solid Tumor	Shanghai Pulmonary Hospital, Shanghai, China	P2	B (60)
Fludarabine Solid Tumor	National Cancer Institute (NCI)	P2	B (60)
Ipilimumab Solid Tumor	Partner Therapeutics, Inc.	P2	B (60)
Nivolumab Solid Tumor	Boehringer Ingelheim	P2	B (60)
Toripalimab Solid Tumor	Suzhou Abogen Biosciences Co., Ltd.	P2	B (60)
Calcium folinate pentahydrate Solid Tumor	Mirati Therapeutics Inc.	P3	B (59)
CIS-DIAMMINEDICHLOROPLATINUM II Solid Tumor	Mabwell (Shanghai) Bioscience Co., Ltd.	P3	B (59)
Eloxatin Solid Tumor	Mirati Therapeutics Inc.	P3	B (59)
FLUOROURACILUM Solid Tumor	Mirati Therapeutics Inc.	P3	B (59)
Binimetinib Solid Tumor	Pfizer	P4	B (58)
Dabrafenib Solid Tumor	Cancer Research UK	P4	B (58)
Encorafenib Solid Tumor	Pfizer	P4	B (58)
Ibrutinib Solid Tumor	National University Hospital, Singapore	P4	B (58)
Capecitabine Solid Tumor	I-Mab Biopharma US Limited	P3	B (58)
Docetaxel Solid Tumor	Mirati Therapeutics Inc.	P3	B (58)

Showing 1 to 25 of 480 assets

PreviousPage 1 of 20Next